Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

NCT05377827 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05377827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05377827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Suspended
Start date
October 10, 2023
Completion date
June 30, 2027
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, adult t cell leukemia, adult t cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, enteropathy-associated t-cell lymphoma, extranodal nk/t-cell lymphoma, hepatosplenic t-cell lymphoma, monomorphic epitheliotropic intestinal t-cell lymphoma, peripheral t cell lymphoma, primary cutaneous gamma-delta t-cell lymphoma, sezary syndrome, t cell prolymphocytic leukemia, t-cell non-hodgkin lymphoma, transformed mycosis fungoides